This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Smith & Nephew Becomes Pharma Family Factor

NEW YORK ( TheStreet) -- Any decent management team will tell you that turning around a struggling business is never easy. If that company happens to be in the realm of medical device technology, case studies are rampant.

Companies like Boston Scientific (BSX), Johnson & Johnson (JNJ) and Stryker (SYK) have gone through several years of "reconstructive surgery" to nurse their businesses back to health. And the Street has been anything but patient or forgiving during that span. To that end, it's a little surprising the degree to which the benefit of the doubt is being granted to Smith & Nephew (SNN - Get Report).

Over the past couple of years, Smith & Nephew's growth has underperformed industry peers like Zimmer (ZMH) and Stryker. The company has steadily lost market share to (among others) Johnson & Johnson in areas like orthopedic implants for hips and knees. And this occurred as management dealt with problems related to the recalls of R3 Acetabular system linked to bone and muscle complications in patients.

Smith & Nephew has not been alone in product recalls. Johnson & Johnson, Stryker and St. Jude Medical (STJ) have dealt with similar issues. Smith & Nephew has not. Today, Smith & Nephew is regarded as one of the best medical device companies on the market.

I haven't heard anyone say this, but there's a lot of evidence pointing to management's deal for Healthpoint Biotherapeutics two years ago as the cause for this turnaround.

The $782 million all-cash deal drew a lot of criticism. Some analysts didn't believe Healthpoint, which was projected to produce $190 million in revenue, was worth the price Smith & Nephew was paying. This is even though Healthpoint was (then) growing revenue at 25% year-over-year. I disagreed.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SNN $34.28 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%
GOOG $548.34 0.00%
TSLA $185.00 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs